Compare ClearPoint Neuro Inc (CLPT) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Charles River Laboratories Intl. Inc — how do they compare? ClearPoint Neuro Inc trades at $15.17 (market cap $454.21M), while Charles River Laboratories Intl. Inc trades at $287.89 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 29.6× ClearPoint Neuro Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | CRL | |
|---|---|---|
Market Cap | $454.21M | $13.46B |
Sector | Health | Health |
52-Week High | $29.60 | $282.00 |
52-Week Low | $8.66 | $145.57 |
Enterprise Value | $488.79M | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.20, up 4.32% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings estimates, with a net income margin of -81.76%. Recent news highlights regulatory progress with partners and expansion into focused ultrasound technology.
The outlook remains speculative with high growth potential in neurotherapy markets, but significant execution and profitability risks persist. Analyst consensus is unanimously bullish, though sustained losses and cash burn require careful monitoring for long-term investors.
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
